日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D

七抗耐药性骨髓瘤的演变涉及 CD38、BCMA 和 GPRC5D 的依次丢失。

Riedhammer, C; Truger, M; Lee, H; Leypoldt, L B; Meggendorfer, M; Hutter, S; Müller, H; Mersi, J; Kadel, S K; Buchwald, T; Kosch, R; Helal, M; Afrin, N; Rosenwald, A; Gerhard-Hartmann, E; Brioli, A; Krönke, J; Haferlach, T; Haferlach, C; Weisel, K C; Neri, P; Einsele, H; Kortüm, K M; Waldschmidt, J M; Bahlis, N; Weinhold, N; Rasche, L

Molecular diagnostics in cancer patients with suspected respiratory mold infections

对疑似呼吸道霉菌感染的癌症患者进行分子诊断

Rickerts, V; Springer, J; Gerkrath, J; Korczynski, D; Kessel, J; Wieters, I; Liebregts, T; Steinmann, J; Cornely, O A; Koehler, P; Schwartz, S; Elgeti, T; Meintker, L; Krause, S W; Held, J; Heinz, W J; Willinger, B; Maschmeyer, G; Voigt, S; Reiche, J; Vehreschild, J J; Einsele, H; Teschner, D; Löffler, J

Real-world analysis of teclistamab in 123 RRMM patients from Germany

德国123例复发/难治性多发性骨髓瘤患者接受teclistamab真实世界分析

Riedhammer, C; Bassermann, F; Besemer, B; Bewarder, M; Brunner, F; Carpinteiro, A; Einsele, H; Faltin, J; Frenking, J; Gezer, D; Goldman-Mazur, S; Hänel, M; Hoegner, M; Kortuem, K M; Krönke, J; Kull, M; Leitner, T; Mann, C; Mecklenbrauck, R; Merz, M; Morgner, A; Nogai, A; Raab, M S; Teipel, R; Wäsch, R; Rasche, L

Dismal prognosis of Pneumocystis jirovecii pneumonia in patients with multiple myeloma

多发性骨髓瘤患者发生卡氏肺囊虫肺炎预后极差

Riedhammer, C; Düll, J; Kestler, C; Kadel, S; Franz, J; Weis, P; Eisele, F; Zhou, X; Steinhardt, M; Scheller, L; Mersi, J; Waldschmidt, J M; Einsele, H; Turnwald, D; Kortüm, K M; Surat, G; Rasche, L

Tracking the progeny of adoptively transferred virus-specific T cells in patients posttransplant using TCR sequencing

利用TCR测序追踪移植后患者体内过继转移的病毒特异性T细胞的后代

Huisman, W; Roex, M C J; Hageman, L; Koster, E A S; Veld, S A J; Hoogstraten, C; van Balen, P; van Egmond, H M; van Bergen, C A M; Einsele, H; Germeroth, L; Amsen, D; Falkenburg, J H F; Jedema, I

P23 EMAGINE/CARTITUDE-6: A RANDOMIZED PHASE 3 STUDY OF DVRD FOLLOWED BY CILTACABTAGENE AUTOLEUCEL VERSUS DVRD FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANT IN TRANSPLANT-ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

P23 EMAGINE/CARTITUDE-6:一项随机3期研究,比较DVRD方案序贯CILTACABTAGENE AUTOLEUCEL方案与DVRD方案序贯自体干细胞移植治疗新诊断的多发性骨髓瘤移植适应症患者的疗效。

Del Giudice, Maria Livia; Galimberti, Sara; Buda, Gabriele; Broijl, A; San-Miguel, J; Suzuki, K; Krishnan, A; van de Donk, N; Cook, G; Jakubowiak, A; Madduri, D; Afifi, S; Stevens, A; Schecter, J; Deraedt, W; Kuppens, S; Mistry, P; Pacaud, L; Boccadoro, M; Gay, F; Mina, R; Rasche, L; Moreau, P; Mateos, M; Einsele, H; Sonneveld, P

PB2266: INFECTIVE ENDOCARDITIS IN NEUTROPENIC PATIENTS: A SYSTEMATIC REVIEW

PB2266:中性粒细胞减少症患者的感染性心内膜炎:系统评价

Tesio, Melania; Morgan, Kate; Paiva, Bruno; Al Farttoosi, Mohammed; Einsele, H; Frikha, R; Belguith, I; Leila, K; Lan, D; Shi, L; Gao, L; Guaraná, M; Beteille, E; Nucci, M

P1456: EARLY SAFETY AND CLINICAL COURSE OF PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MEASURABLE RESIDUAL DISEASE RECEIVING GTA002, AN OFF-THE-SHELF, EX VIVO-CULTURED ALLOGENEIC NK CELL PREPARATION

P1456:接受 GTA002(一种现成的体外培养同种异体 NK 细胞制剂)治疗的急性髓系白血病伴可测量残留病灶患者的早期安全性和临床病程

Feurle, Gerhard E; Moos, Verena; Einsele, H; Moreau, P; Delforge, M; van de Donk, N W; Ghilotti, F; Diels, J; Elsada, A; Strulev, V; Pei, L; Kobos, R; Smit, J; Slavcev, M; Weisel, K; Mateos, M-V; Einsele, H; Moreau, P; De Stefano, V; Dytfeld, D; Angelucci, E; Benjamin, R; Goldschmidt, H; van de Donk, N W; Besemer, B; Scheid, C; Vij, R; ’. Groen-Damen, E I; Semerjian, M; Strulev, V; Schecter, J M; Roccia, T; Nesheiwat, T; Wapenaar, R; Weisel, K; Mateos, M-V; Heuser, M; Fiedler, W; Block, A; de Leeuw, D C; van de Loosdrecht, A; Astrid Tschan-Plessl, A; Passweg, J; Kloos, A; Schwarzer, A; Venturini, L; Duru, A D; Pinkernell, K; Ganser, A

P935: REAL WORLD COMPARATIVE ANALYSIS OF THE EFFICACY OF TECLISTAMAB VERSUS CURRENT TREATMENTS IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE LOCOMOTION STUDY

P935:LOCOMOTION 研究中 TECLISTAMAB 与现有疗法在接受过三类药物治疗的复发/难治性多发性骨髓瘤患者中的疗效真实世界比较分析

van Schie, P M; Fletcher, M; van de Donk, N W; Guo, S; Shi, L; Lord-Bessen, J; Tang, D; Karlin, L; Weisel, K; Ramasamy, K; Abad, P C; Amin, A; Amin, S; Lonial, S; Einsele, H; Moreau, P; Delforge, M; van de Donk, N W; Ghilotti, F; Diels, J; Elsada, A; Strulev, V; Pei, L; Kobos, R; Smit, J; Slavcev, M; Weisel, K; Mateos, M-V

P898: COMPARISON OF TECLISTAMAB WITH BELANTAMAB MAFODOTIN IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA USING MATCHING-ADJUSTED INDIRECT TREATMENT COMPARISON

P898:采用匹配调整的间接治疗比较方法,比较 TECLISTAMAB 与 BELANTAMAB MAFODOTIN 在接受过三类药物治疗的复发/难治性多发性骨髓瘤患者中的疗效

Sung, Tzu-I; Chen, Pau-Chung; Jyuhn-Hsiarn Lee, Lukas; Lin, Yi-Ping; Hsieh, Gong-Yih; Wang, Jung-Der; Weisel, K; Mateos, M-V; Vincent, L; Martin, T; Berdeja, J G; Jakubowiak, A; Jagannath, S; Lin, Y; Thilakarathne, P; Ghilotti, F; Diels, J; Haefliger, B; Hague, C; Gonzalez, A; Schecter, J M; Gries, K S; Strulev, V; Nesheiwat, T; Pacaud, L; Einsele, H; Moreau, P; Delforge, M; Usmani, S Z; van de Donk, N W; Garfall, A L; Moreau, P; Oriol, A; Nooka, A K; Rosinol, L; Bahlis, N; Rodriguez-Otero, P; Martin, T; Diels, J; Van Sanden, S; Pei, L; Ammann, E; Kobos, R; Slavcev, M; Smit, J; Londhe, A; Krishnan, A